Skip to main content
Jennifer Chan, MD, Hematology, Boston, MA

JenniferAngChanMD

Hematology Boston, MA

Hematologic Oncology

Instructor in Medicine, Dana-Farber Cancer Institute

Dr. Chan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Chan's full profile

Already have an account?

  • Office

    44 Binney St
    # Dana
    Boston, MA 02115
    Phone+1 617-632-6315
    Fax+1 617-632-5370

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2003 - 2006
  • Brigham and Women's Hospital
    Brigham and Women's HospitalResidency, Internal Medicine, 2000 - 2003
  • Harvard Medical School
    Harvard Medical SchoolClass of 2000

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2003 - 2026
  • NH State Medical License
    NH State Medical License 2023 - 2025
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Other

Press Mentions

  • Cabozantinib Improves PFS in Patients with Previously Treated, Progressive Advanced Extrapancreatic or Pancreatic Neuroendocrine Tumours
    Cabozantinib Improves PFS in Patients with Previously Treated, Progressive Advanced Extrapancreatic or Pancreatic Neuroendocrine TumoursOctober 25th, 2024
  • Cabozantinib Improves PFS for Advanced Neuroendocrine Tumors
    Cabozantinib Improves PFS for Advanced Neuroendocrine TumorsSeptember 17th, 2024
  • Team Publishes Results from Clinical Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors
    Team Publishes Results from Clinical Trial Evaluating Cabozantinib in Advanced Neuroendocrine TumorsSeptember 16th, 2024

Professional Memberships